Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2014-003655-66
    Sponsor's Protocol Code Number:I4T-MC-JVDC
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2020-11-04
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2014-003655-66
    A.3Full title of the trial
    A Phase 3, Randomized, Double-Bind, Placebo-Controlled Study of Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or after Platinum-Based Theraply
    Studio di Fase 3, Randomizzato, in Doppio Cieco, Controllato con Placebo di Ramucirumab più Docetaxel verso Placebo più Docetaxel in Pazienti con Carcinoma Uroteliale Localmente Avanzato Non resecabile o Metastatico, che hanno avuto Progressione durante o dopo la terapia a Base di Platino.

    A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of Ramucirumab plus Docetaxel Versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed Following Platinum-Based Therapy
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Study of Ramucirumab plus Docetaxel in Participants with Urothelial Cancer.
    Uno studio di Ramucirumab più Docetaxel in Partecipanti con carcinoma Uroteliale
    A.3.2Name or abbreviated title of the trial where available
    RANGE
    RANGE
    A.4.1Sponsor's protocol code numberI4T-MC-JVDC
    A.5.4Other Identifiers
    Name:NANumber:I4T-MC-JVDC
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorELI LILLY & COMPANY, LILLY CORPORATE CENTER
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportEli Lilly and Company
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationEli Lilly
    B.5.2Functional name of contact pointClinical Trial Registry Ofifce
    B.5.3 Address:
    B.5.3.1Street AddressLilly Corporate Center, DC 1526
    B.5.3.2Town/ cityIndianapolis
    B.5.3.3Post code46285
    B.5.3.4CountryUnited States
    B.5.4Telephone number001877
    B.5.5Fax number001877
    B.5.6E-mailEU_Lilly_Clinical_Trials@lilly.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Cymranza
    D.2.1.1.2Name of the Marketing Authorisation holderEli Lilly Nederland B.V.
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRamucirumab
    D.3.2Product code [LY3009806]
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNramucirumab
    D.3.9.1CAS number 947687-13-0
    D.3.9.2Current sponsor codeNA
    D.3.9.3Other descriptive nameramucirumab
    D.3.9.4EV Substance Coderamucirumab
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name NA
    D.2.1.1.2Name of the Marketing Authorisation holderNA
    D.2.1.2Country which granted the Marketing AuthorisationFrance
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDocetaxel
    D.3.2Product code [Docetaxel]
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDOCETAXEL
    D.3.9.2Current sponsor codeNA
    D.3.9.3Other descriptive nameDocetaxel
    D.3.9.4EV Substance CodeSUB12492MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboConcentrate for solution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Locally advanced or unresectable or metastatic urothelial carcinoma who
    have had disease progression on or after one prior first-line platinumbased
    chemotherapy
    Carcinoma Uroteliale Localmente Avanzato Non resecabile o Metastatico, che hanno avuto Progressione durante o dopo la terapia a Base di Platino
    E.1.1.1Medical condition in easily understood language
    Cancer of the bladder and urinary tract
    Carcinoma della vescica e del tratto urinario
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10064467
    E.1.2Term Urothelial carcinoma
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this study is to compare the progression-free
    survival (PFS) of ramucirumab in combination with docetaxel with the
    PFS of placebo in combination with docetaxel, in patients with locally
    advanced or unresectable or metastatic urothelial carcinoma who have
    had disease progression on or after one prior first-line platinum-based
    chemotherapy
    L’obiettivo primario di questo studio è confrontare la sopravvivenza libera da progressione (PFS) ottenuta con ramucirumab in associazione a docetaxel rispetto alla PFS ottenuta con placebo in associazione a docetaxel in pazienti con carcinoma uroteliale localmente avanzato oppure non resecabile o metastatico nei quali la malattia sia progredita durante o dopo una precedente chemioterapia di prima linea a base di platino.

    E.2.2Secondary objectives of the trial
    The secondary objectives of this study are to compare each of the
    following variables between the treatment arms:
    • overall survival (OS) time
    • objective response rate (ORR; complete response [CR] + partial
    response [PR]) and disease control rate (DCR)
    • duration of response (DOR)
    • safety profile
    • patient-reported outcome (PRO) measures (European Organisation for
    Research and Treatment of Cancer Quality of Life Questionnaire-C30
    [EORTC QLQ-C30] and EQ 5D-5L questionnaires)
    Secondary objectives also include the evaluation of:
    • the pharmacokinetic profile of ramucirumab
    • the immunogenicity of ramucirumab (anti-ramucirumab antibodies)
    Gli obiettivi secondari dello studio consistono nella comparazione di ciascuna delle seguenti variabili tra i bracci di trattamento:
    • tempo di sopravvivenza globale (OS)
    • tasso di risposta obiettiva (ORR; risposta completa [CR] + risposta parziale [PR]) e tasso di controllo della malattia (DCR)
    • durata della risposta (DOR)
    • profilo di sicurezza
    • misure di outcome riferito dal paziente (PRO) (questionari EORTC QLQ-C30 [European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30] ed EQ 5D-5L)
    Gli obiettivi secondari includono inoltre la valutazione dei seguenti elementi:
    • profilo farmacocinetico di ramucirumab
    • immunogenicità di ramucirumab (anticorpi anti-ramucirumab)
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1) Histologically or cytologically confirmed, locally advanced orunresectable or metastatic urothelial (transitional cell) carcinoma of the bladder, urethra, ureter, or renal pelvis. Patients with mixed pathology are eligible only if they have predominantly transitional cell tumor based on local pathology review.
    2) Demonstrated disease progression while on a platinum-containing regimen in the first-line setting or within 14 months after completing the first-line platinum regimen. Patients who received treatment with one immune checkpoint inhibitor (for example PD-1, PDL1, CTLA4) regimen may have a longer interval since prior platinum-containing therapy (=24 months), as noted in Inclusion Criterion [4].
    3) A life expectancy of =3 months, in the judgment of the investigator.
    4) The patient has received no more than one prior systemic chemotherapy regimen in the relapsed or metastatic setting. Prior cytotoxic therapy in an adjuvant or neoadjuvant setting is not considered as a prior line of systemic chemotherapy in the relapsed or metastatic setting. Prior treatment with intravesicular chemotherapy, bacillus Calmette-Guérin (BCG), or platinum given as a radiation sensitizing agent will not be considered as a systemic line of treatment. Prior treatment with no more than one prior immune checkpoint inhibitor is permitted and will not be considered as a line of systemic chemotherapy. Patients enrolling after immune checkpoint inhibitor therapy must have demonstrated disease progression while on that therapy or within 24 months after the last dose of that therapy.
    5) Measurable disease or nonmeasurable but evaluable disease as defined by Response Evaluation Criteria in Solid Tumors, Version 1.1
    6) Resolution, except where otherwise stated in the inclusion criteria, of all clinically significant toxic effects of prior chemotherapy, surgery, or radiotherapy to Grade =1 by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0.
    7) Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
    8) The patient has adequate hematologic function and has not received blood or blood components transfusion within 2 weeks prior to thelaboratory test.
    9) Adequate coagulation function as defined by international normalized ratio (INR) =1.5 and a partial thromboplastin time (PTT) =1.5 × upper limit of normal (ULN) if not receiving anticoagulation therapy. Patients on full-dose anticoagulation must be on a stable dose of oral anticoagulant or low molecular weight heparin. If on warfarin, the patient must have an INR =3 and have no active bleeding (defined as within 14 days prior to randomization, excluding trace hematuria) or pathological condition that carries a high risk of bleeding.
    10) Adequate hepatic function as defined by bilirubin within normal limits (WNL), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =3.0 × ULN, and alkaline phosphatase (AP) =2.5 × ULN.
    11) The patient does not have:• cirrhosis at a level of Child-Pugh B (or worse), or• cirrhosis and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is defined as ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis.
    12) Adequate renal function as defined by creatinine clearance >30
    mL/min either as measured by 24-hour urine collection or as calculated. 13) The patient's urinary protein is =1+ on dipstick or routine urinalysis; if urine protein =2+, a 24-hour urine collection must demonstrate <2 g of protein in 24 hours.
    • Il paziente presenta carcinoma uroteliale (a cellule di transizione) della vescica, dell’uretra, dell’uretere o della pelvi renale localmente avanzato oppure non resecabile o metastatico, istologicamente o citologicamente confermato. I pazienti con patologia mista saranno considerati idonei unicamente in caso di tumore prevalentemente a cellule di transizione sulla base della valutazione effettuata dal patologo locale.
    • Il paziente presenta progressione di malattia dimostrata durante regime a base di platino in setting di prima linea o nei 14 mesi successivi alla conclusione del regime di prima linea a base di platino. I pazienti sottoposti a trattamento con un inibitore di checkpoint immunitario (ad es. PD-1, PDL1 o CTLA4) dopo terapia a base di platino possono avere un intervallo post-terapia a base di platino più lungo (=24 mesi); tali pazienti sono considerati eleggibili.
    • Il paziente ha ricevuto non più di un regime chemioterapico sistemico pregresso nel setting di malattia recidivante o metastatica. Una precedente terapia citotossica in setting adiuvante o neoadiuvante non è considerata come una linea pregressa di chemioterapia sistemica in setting recidivante o metastatico. Un precedente trattamento con chemioterapia endovescicale, bacillo di Calmette-Guérin (BCG) o platino somministrato come radio-sensibilizzante non sarà considerato come una linea di trattamento sistemico. Il trattamento pregresso con non più di un inibitore di checkpoint immunitario è consentito e non sarà considerato come una linea di chemioterapia sistemica. I pazienti arruolati dopo terapia con inibitore di checkpoint immunitario devono avere progressione di malattia dimostrata durante tale trattamento o nei 24 mesi successivi alla somministrazione dell’ultima dose di tale trattamento.
    • Il paziente presenta malattia misurabile o non misurabile ma comunque valutabile secondo la definizione fornita dalla versione 1.1 del Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
    • Il paziente presenta un performance status ECOG (Eastern Cooperative Oncology Group) di 0 o 1.
    • Il paziente acconsente a fornire campioni di sangue, urine e tessuti per fini di ricerca. La fornitura di campioni di sangue e di urine è una condizione obbligatoria per la partecipazione allo studio, fatta salva l’esistenza di restrizioni imposte dalle norme locali. Qualora siano disponibili campioni di tumore precedentemente archiviati, in assenza di restrizioni previste dalle norme locali, la messa a disposizione del tessuto tumorale archiviato è obbligatoria. Qualora non sia disponibile un campione in archivio sarà necessario fornire una nuova biopsia a condizione che la procedura sia sicura e fattibile.
    • Il paziente ha un’adeguata funzionalità d’organo.
    E.4Principal exclusion criteria
    The patient has received more than one prior systemic
    chemotherapy regimen for metastatic disease (except as noted in
    Inclusion Criterion [4]). A treatment regimen must consist of a
    minimum of 2 cycles to be considered as a prior regimen.
    1) The patient has received prior systemic taxane therapy for TCC of the bladder, urethra, ureter, or renal pelvis in any setting (neoadjuvant,
    adjuvant, metastatic). Prior intravesical taxane therapy is allowed and will not be considered as a prior line of systemic therapy.
    2) The patient has received more than one prior antiangiogenic agent
    (that is, bevacizumab, sorafenib, sunitinib) for TCC of the urothelium.
    3) The patient has received radiation therapy (including full-dose pelvic
    radiotherapy) within 4 weeks prior to randomization or has not
    recovered from toxic effects of the treatment that was given >4 weeks
    prior to randomization. Single fraction radiotherapy for palliative bone
    stabilization within 4 weeks prior to randomization is allowed. If any
    tumor lesion is administered radiotherapy, then it cannot be considered
    for response assessment.
    4) The patient has a history of uncontrolled hereditary or acquired
    bleeding or thrombotic disorders.
    5) The patient has experienced a Grade =3 bleeding event (for ex, via gastric ulcers, gastric varices, rectal bleeding, or gross hematuria) within 3 months prior to randomization. Patients must have
    complete resolution of any prior bleeding event prior to randomization.
    6) The patient has uncontrolled intercurrent illness, including, but not limited to symptomatic anemia, uncontrolled hypertension (>160 mm Hg
    systolic and/or >100 mm Hg diastolic, despite antihypertensive medication), symptomatic congestive heart failure, unstable angina
    pectoris, symptomatic or poorly controlled cardiac arrhythmia, psychiatric illness, or any other serious uncontrolled medical disorders in
    the opinion of the investigator.
    7) The patient has experienced any arterial or venothrombotic or
    thromboembolic events, including, but not limited to myocardial
    infarction, transient ischemic attack, or cerebrovascular accident, within
    6 months prior to randomization.
    8) The patient has known untreated brain metastases, uncontrolled
    spinal cord compression, or leptomeningeal disease. (Note: A brain
    scan via computed tomography [CT] with contrast or magnetic
    resonance imaging [MRI] is to be performed only after study eligibility is
    confirmed, to detect the presence of intracranial metastasis.)
    9) The patient has an ongoing or active infection requiring antibiotic,
    antifungal, or antiviral therapy.
    10) The patient has known human immunodeficiency virus (HIV)
    infection or acquired immunodeficiency syndrome-related illness.
    11) The patient has received a prior autologous or allogeneic organ or
    tissue transplantation.
    12) The patient:
    • received chemotherapy within 21 days prior to randomization; and/or
    • is currently enrolled in, or discontinued within 21 days prior to
    randomization from, a clinical trial involving an investigational product
    (IP) or non-approved use of a drug or device, or is concurrently enrolled in any other type of medical research judged not to be scientifically or
    medically compatible with this study; and/or
    • was treated with antiangiogenic therapy within 28 days prior to
    randomization.
    13) The patient has undergone major surgery within 28 days prior to
    randomization or subcutaneous venous access device placement within 7
    days prior to randomization.
    1) Il paziente ha ricevuto più di un regime pregresso di chemioterapia sistemica per malattia metastatica (fatte salve le eccezioni illustrate nel Criterio di inclusione [4]). Un regime terapeutico deve consistere di almeno 2 cicli per essere considerato un regime pregresso.
    2)Il paziente è stato sottoposto a terapia pregressa con taxani per carcinoma a cellule di transizione di vescica, uretra, uretere o pelvi renale in qualsiasi setting (neoadiuvante, adiuvante, metastatico). Una precedente terapia endovescicale con taxani è consentita e non sarà considerata come una linea pregressa di terapia sistemica.
    3)Il paziente ha ricevuto più di un agente antiangiogenico (ovvero, bevacizumab, sorafenib, sunitinib) per il carcinoma a cellule di transizione dell’urotelio.
    4)Il paziente è stato sottoposto a radioterapia (compresa la radioterapia pelvica a dose piena) nelle 4 settimane precedenti la randomizzazione o non si è ripreso dagli effetti tossici del trattamento somministrato >4 settimane prima della randomizzazione. La radioterapia in frazione singola per la stabilizzazione palliativa delle metastasi ossee nelle 4 settimane precedenti la randomizzazione è consentita. In caso di trattamento radioterapico su una o più lesioni tumorali, queste ultime non potranno essere considerate per la valutazione della risposta.
    5)Il paziente ha un’anamnesi positiva per disturbi emorragici o trombotici ereditari o acquisiti non controllati.
    6) Il paziente è andato incontro a un sanguinamento di grado =3 (ad es. da ulcere o varici gastriche, sanguinamento rettale o ematuria macroscopica) nei 3 mesi precedenti la randomizzazione. Gli eventuali eventi pregressi di sanguinamento devono essersi risolti in modo completo prima della randomizzazione.
    7) Il paziente presenta una patologia intercorrente non controllata quale, in via esemplificativa, anemia sintomatica, ipertensione non controllata (pressione sistolica >160 mmHg e/o pressione diastolica 100 mmHg, nonostante il trattamento con antipertensivi), insufficienza cardiaca congestizia sintomatica, angina pectoris instabile, aritmia cardiaca sintomatica o poco controllata, disturbi psichiatrici o qualsiasi altra condizione medica seria e non controllata secondo il giudizio dello sperimentatore.
    8)Il paz. è andato incontro a eventi trombotici o tromboembolici arteriosi o venosi quali, in via esemplificativa, infarto del miocardio, attacco ischemico transitorio o accidente cerebrovascolare nei 6 mesi precedenti la randomizzazione.
    9)Presenza nota di metastasi cerebrali non trattate, compressione del midollo spinale non controllata o malattia leptomeningea. (Nota: la tomografia computerizzata [TC], con o senza mezzo di contrasto, o la risonanza magnetica [RM] dell’encefalo devono essere eseguite solo dopo la conferma dell’eleggibilità del paziente allo studio al fine di rilevare la presenza di metastasi intracraniche).
    10) Il paziente ha un’infezione in corso o attiva che richiede il trattamento con terapia antibiotica, antifungina o antivirale.
    11) Il paziente ha un’infezione nota da virus dell’immunodeficienza umana (HIV) o una malattia correlata alla sindrome da immunodeficienza acquisita.
    12) Il paziente è stato precedentemente sottoposto a un trapianto autologo o allogenico di organi o tessuti.
    13) Il paz.:
    • è stato sottoposto a chemioterapia nei 21 giorni precedenti la randomizzazione; e/o
    • è attualmente arruolato in uno studio clinico che prevede l’uso di un prodotto sperimentale o l’uso non approvato di un farmaco o un dispositivo o si è ritirato da tale studio nei 21 giorni precedenti la randomizzazione; oppure è attualmente arruolato in un qualsiasi altro tipo di ricerca clinica ritenuto non compatibile con il presente studio dal punto di vista scientifico o medico; e/o
    • è stato sottoposto a terapia antiangiogenica nei 28 giorni precedenti la randomizzazione.
    E.5 End points
    E.5.1Primary end point(s)
    To test PFS superiority with this assumption: The PFS hazard ratio for
    treatment group (ramucirumab plus docetaxel) vs control group
    (placebo plus docetaxel) is 0.70.

    Testare la superiorità in termini di PFS sulla base del seguente assunto: l’hazard ratio per la PFS per il gruppo di trattamento (ramucirumab più docetaxel) vs. il gruppo di controllo (placebo più docetaxel) è 0,70.
    E.5.1.1Timepoint(s) of evaluation of this end point
    The primary analysis of PFS will be performed when a minimum of 331 PFS events have been observed from the first 437 randomized patients with 0.05 Alpha (two sided).
    L’analisi primaria della PFS verrà eseguita nel momento in cui tra i primi 437 pazienti randomizzati saranno stati osservati almeno 331 eventi di PFS con alfa pari a 0,05 (test a due code).
    E.5.2Secondary end point(s)
    • overall survival (OS) time
    • objective response rate (ORR; complete response [CR] + partial
    response [PR]) and disease control rate (DCR)
    • duration of response (DOR)
    • safety profile
    • patient-reported outcome (PRO) measures (EORTC QLQ-C30 and EQ-
    5D-5L questionnaires).
    Secondary objectives also include the evaluation of:
    • the pharmacokinetic profile of ramucirumab
    - the immunogenicity of ramucirumab (anti-ramucirumab antibodies)
    • tempo di sopravvivenza globale (OS)
    • tasso di risposta obiettiva (ORR; risposta completa [CR] + risposta parziale [PR]) e tasso di controllo della malattia (DCR)
    • durata della risposta (DOR)
    • profilo di sicurezza
    • misure di outcome riferito dal paziente (PRO) (questionari EORTC QLQ-C30 ed EQ-5D-5L). Gli obiettivi secondari includono inoltre la valutazione dei seguenti elementi:
    • profilo farmacocinetico di ramucirumab
    - immunogenicità di ramucirumab (anticorpi anti-ramucirumab)
    E.5.2.1Timepoint(s) of evaluation of this end point
    A gatekeeping design will be used to assess PFS, OS, and ORR. The OS
    superiority is tested only if PFS superiority test is significant. Similarly,
    the ORR superiority is tested only if OS superiority test is significant.
    An interim OS analysis will be performed at PFS final analysis with
    Bonferroni alpha splitting of 0.001(two sided); all patients who have
    been randomized at that point will be used to compare OS between the 2 arms.
    Per la valutazione della PFS, dell’OS e dell’ORR si utilizzerà un disegno “a soglia” (gatekeeping). La superiorità in termini di OS è testata soltanto se il test di superiorità per la PFS risulta significativo. Analogamente, la superiorità in termini di ORR viene testata soltanto se il test di superiorità per l’OS risulta significativo. All’analisi finale della PFS sarà eseguita un’analisi ad interim con alfa corretto secondo il metodo di Bonferroni pari a 0,001 (test a due code); per il confronto dell’OS fra i due bracci saranno utilizzati tutti i pazienti randomizzati fino a quel momento. L’analisi finale dell’OS sarà eseguita quando saranno stati osservati 382 eventi di OS con alfa pari a 0,049 (test a due code).
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Patient Reported Outcomes, Immunogenicity
    Outcome riportati dal paziente, immunogenicità
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA48
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Belgium
    Canada
    Denmark
    France
    Germany
    Greece
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months9
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months9
    E.8.9.2In all countries concerned by the trial days21
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 179
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 345
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state20
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 250
    F.4.2.2In the whole clinical trial 524
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Nessuno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-06-26
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-05-06
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 21:40:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA